balance equationreview2023-12-31
Difference 3420000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
Unavailable
Fiscal year ended 2025-12-31Operating income
-$11.63M
Fiscal year ended 2025-12-31Free cash flow
-$10.83M
Fiscal year ended 2025-12-31Silexion Therapeutics Corp (SLXN) reported net income of -$11.91M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Silexion Therapeutics Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | Unavailable | Unavailable | Unavailable |
| Cost of revenue | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable |
| Operating income | -$11.63M | -$12.57M | -$4.68M |
| Net income | -$11.91M | -$16.52M | -$5.11M |
| Research & development | $7.14M | $5.82M | $3.71M |
| Weighted-average diluted shares | shares 1.33M | Unavailable | Unavailable |
| Pretax income | -$11.91M | -$16.51M | -$5.08M |
| Income tax expense | $3.00K | $10.00K | $32.00K |
| Diluted EPS | $8.96 | $394.94 | $44.23 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable |
| General & administrative | $4.49M | $6.76M | $973.00K |
| Selling & marketing | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash & equivalents | $5.99M | $1.19M | $4.60M |
| Total assets | $7.22M | $2.86M | $5.26M |
| Current assets | $6.64M | $2.25M | $4.98M |
| Total liabilities | $4.61M | $6.85M | $2.26M |
| Current liabilities | $2.76M | $3.52M | $2.20M |
| Total equity incl. NCI | $2.60M | -$3.99M | $3.00M |
| Temporary (mezzanine) equity | Unavailable | $0 | $3.42M |
| Inventory | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable |
| Accounts payable | $787.00K | $929.00K | $319.00K |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating cash flow | -$10.82M | -$8.40M | -$4.53M |
| Capital expenditures | $9.00K | $22.00K | $12.00K |
| Investing cash flow | -$14.00K | -$22.00K | $573.00K |
| Financing cash flow | $15.64M | $5.10M | $522.00K |
| Net change in cash | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $134.00K | $5.86M | $130.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free cash flow | -$10.83M | -$8.42M | -$4.54M |
| Gross margin | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable |
| Current ratio | 2.41x | 0.64x | 2.27x |
| Revenue YoY growth | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SLXN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.